argenx to Present at TD Cowen 45th Annual Healthcare Conference

Rhea-AI Summary

argenx, a global immunology company focused on improving lives of people with severe autoimmune diseases, has announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference. The presentation is scheduled for Monday, March 3, 2025 at 11:50 a.m. ET.

Investors and interested parties can access a live webcast of the presentation through the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will remain available on the company website for approximately 30 days following the presentation.

argenx is listed on both Euronext and Nasdaq under the ticker symbol ARGX.

News Market Reaction – ARGX

-0.19%

-0.19% Session move

In the trading session that priced this news, ARGX declined 0.19%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

February 25, 2025

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45^th Annual Healthcare Conference on Monday, March 3, 2025 at 11:50 a.m. ET.

A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.

Media:

Ben Petok
bpetok@argenx.com

Investors:

Alexandra Roy (US)
aroy@argenx.com

Lynn Elton (EU)
lelton@argenx.com

FAQ

When is Tim Van Hauwermeiren presenting at the TD Cowen Healthcare Conference for ARGX?

Tim Van Hauwermeiren, CEO of argenx (ARGX), will present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025 at 11:50 a.m. ET.

How can investors access argenx's (ARGX) presentation at the TD Cowen conference?

Investors can access a live webcast of the presentation through the Investors section of the argenx website at argenx.com/investors.

How long will the replay of ARGX's TD Cowen conference presentation be available?

A replay of the webcast will be available on the argenx website for approximately 30 days following the March 3, 2025 presentation.

What exchanges is argenx (ARGX) listed on?

argenx (ARGX) is listed on both Euronext and Nasdaq stock exchanges.

What is argenx's (ARGX) primary business focus?

argenx (ARGX) is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases.